Published in Br J Haematol on January 01, 2004
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Iron-chelating therapy for transfusional iron overload. N Engl J Med (2011) 3.92
Beta-thalassemia. Orphanet J Rare Dis (2010) 3.06
Non-viral causes of hepatocellular carcinoma. World J Gastroenterol (2010) 1.63
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
The life of patients with thalassemia major. Haematologica (2010) 1.12
Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol (2010) 1.04
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson (2009) 1.00
Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol (2013) 0.93
Hepatic iron overload and hepatocellular carcinoma. Liver Cancer (2014) 0.92
Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med (2012) 0.92
MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol (2013) 0.88
Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med (2014) 0.85
Iron homeostasis in the liver. Compr Physiol (2013) 0.84
Measurement of liver fat fraction and iron with MRI and MR spectroscopy techniques. Diagn Interv Radiol (2014) 0.83
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients. BMC Med Ethics (2011) 0.82
In search of the optimal iron chelation therapy for patients with thalassemia major. Haematologica (2011) 0.81
Cancer cells with irons in the fire. Free Radic Biol Med (2014) 0.80
Heterozygous beta-globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C. Gut (2006) 0.79
Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J Gastroenterol (2007) 0.76
Management of the thalassemias. Cold Spring Harb Perspect Med (2013) 0.76
Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia. Biomed Res Int (2014) 0.76
Effect of iron overload on renal functions and oxidative stress in beta thalassemia patients. Saudi Med J (2016) 0.75
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Purging iron from the heart. Br J Haematol (2004) 2.07
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Improved T2* assessment in liver iron overload by magnetic resonance imaging. Magn Reson Imaging (2008) 1.97
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis (2002) 1.63
Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood (2009) 1.62
Malignancies in β-thalassemia patients: first description of two cases of thyroid cancer and review of the literature. Hemoglobin (2011) 1.57
Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin (2003) 1.56
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation. Lancet (2003) 1.48
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. J Magn Reson Imaging (2006) 1.45
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Hb Southern Italy: coexistence of two missence mutations (the Hb Sun Prairie alpha2 130 Ala --> Pro and Hb Caserta alpha2 26 Ala --> Thr) in a single HBA2 gene. Br J Haematol (2008) 1.39
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood (2002) 1.31
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
How I treat transfusional iron overload. Blood (2012) 1.29
A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol (2005) 1.28
Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. NMR Biomed (2007) 1.28
Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med (2008) 1.27
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood (2011) 1.23
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol (2006) 1.21
Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord (2011) 1.21
The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol (2002) 1.21
Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging (2009) 1.21
Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study. Curr Med Res Opin (2008) 1.20
Acquired Pseudoxanthoma elasticum-like syndrome in beta-thalassaemia patients. Br J Haematol (2003) 1.20
An update on iron chelation therapy. Blood Transfus (2012) 1.19
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica (2010) 1.19
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood (2005) 1.17
High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol (2009) 1.16
A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica (2008) 1.16
Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci (2005) 1.14
Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol (2003) 1.13
Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica (2008) 1.13
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica (2006) 1.13
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. Circulation (2013) 1.11
Epigenetic therapy for Friedreich ataxia. Ann Neurol (2014) 1.11
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis (2009) 1.10
Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med (2010) 1.10
Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood (2013) 1.08
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Ment Health (2007) 1.08
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. Am J Hematol (2015) 1.07
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica (2012) 1.07
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther (2007) 1.06
Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: a Webthal study. Circulation (2013) 1.06
Significance of borderline hemoglobin A2 values in an Italian population with a high prevalence of beta-thalassemia. Haematologica (2008) 1.06
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica (2010) 1.04
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther (2007) 1.03